Pharmacological and pharmacokinetic characteristics of YM435, a novel dopamine DA1-Receptor agonist, in anaesthetized dogs

Journal of Pharmacy and Pharmacology

Volumn 49, Issue 9, 1997, Pages 892-896

  Yatsu, Takeyuki ^a   Miyamoto, Ikuo ^a   Kaneko Takanuki, Fumiyo ^a   Watanabe, Takashi ^a   Takenaka, Toichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3,4 DIHYDROXYPHENYL) 1,2,3,4 TETRAHYDRO 7,8 DIHYDROXYISOQUINOLINE; 4 (3,4 DIHYDROXYPHENYL) 7,8 DIHYDROXY 1,2,3,4 TETRAHYDROISOQUINOLINE HYDROCHLORIDE HYDRATE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INFUSION; FEMALE; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; MALE; NONHUMAN; VASODILATATION;

EID: 0030829030     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1997.tb06131.x     Document Type: Article

References (22)

1. 1 agonists: 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. Chem. Pharm. Bull. 39: 2910-2914
2. Anan H., Tanaka, A., Tsuzuki, R., Yokota, M., Yatsu, T., Fujikura, T. (1996) 4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. II. Their renal vasodilation activity and structure-activity relationship. Chem. Pharm. Bull. 44: 1865-1870
3. Crumley, H. J., Pinder, R. M., Hinshaw, W. B., Goldberg, L. I. (1976) Dopamine-like renal and mesenteric vasodilation caused by apomorphine, 6-propylnorapomorphine and 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydro-naphthalene. Nature 259: 584-587
4. Goldberg, L. I., Rajfer, S. I. (1985) Dopamine receptors: applications in clinical cardiology. Circulation 72: 245-248
5. Goldberg, L. I., Hsieh, Y. Y., Resnekov, L. (1977) Newer catecholamines for the treatment of heart failure and shock: an update of dopamine and a first look at dobutamine. Prog. Cardiovasc. Dis. 19: 327-340
6. Hahn, R. A., Wardell, J. R., Sarau, H. M., Ridley, P. T. (1982) Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J. Pharmacol. Exp. Ther. 223, 305-313
7. Hegde, S. S., Ricci, A., Amenta, F., Lokhandwala, M. F. (1989) Evidence from functional and autoradiographic studies for the presence of tubular dopamine-1 receptors and their involvement in the renal effects of fenoldopam. J. Pharmacol. Exp. Ther. 251: 1237-1245
8. 1) receptor agonist, fenoldopam, in human vasculature in vivo and in vitro. Br. J. Clin. Phamacol. 22: 535-540
9. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (1988) The 1988 Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch. Intern. Med. 148: 1023-1038
10. Lappe, R. W., Todt, J. A., Wendt, R. L. (1986) Effects of fenoldopam on regional vascular resistance in conscious spontaneously hypertensive rats. J. Phamacol. Exp. Ther. 236: 187-191
11. Lokhandwala, M. F., Barrett, R. J. (1983) Dopamine receptor agonists in cardiovascular therapy. Drug Dev. Res. 3: 299-310
12. McNay, J. L., MacCannell, K. L., Meyer, M. B., Goldberg, L. I. (1966) Hypotensive effects of dopamine in dogs and hypertensive patients after phenoxybenzamine. J. Clin. Invest. 45: 1045-1046
13. Nabil, R. F. (1978) Nitroglycerin as a hypotensive drug during general anesthesia. Anesthesiology 49: 17-20
14. Palmer, R. F., Lassetter, K. C. (1975) Drug therapy: sodium nitroprusside. N. Engl. J. Med. 292: 294-296
15. Perry, H. M., Schroeder, H. A., Catanzaro, F. J., Moore-Jones, D., Camel, G. H. (1966) Studies on the control of hypertension. VIII. Mortality, morbidity, and remission during 12 years of intensive therapy. Circulation 33: 958-972
16. Pohl, J. E. F, Thurston, H., Swales, J. D. (1974) Hypertension with renal impairment: influence of intensive therapy. Q. J. Med. 43: 569-581
17. Reid, G. M., Muther, R. S. (1987) Nitroprusside-induced acute azotemia. Am. J. Nephrol. 7: 313-315
18. Vidt, D. G. (1986) Current concepts in treatment of hypertensive emergencies. Am. Heart J. 111: 220-225
19. 1 receptor agonist, in anesthetized dogs. Jpn. J. Pharmacol. 55: 334
20. 1 receptor agonist activity of YM435 in the canine renal vasculature. Gen. Pharmacol. In press
21. 1 receptor agonist, in anesthetized dogs. J. Cardiovasc. Pharmacol. 29: 382-388
22. 1 receptor agonist, in anesthetized dogs. Eur. J. Pharmacol. 322: 45-53